检索结果-南通市图书馆

Pharmacological methods for ovarian function and fertility preservation in women with cancer:A literature review

Oncology Research 2024年第8期32卷 1309-1322页

作者： ANA S.CVETANOVIC MATTEO LAMBERTINI KEVIN PUNIE GORANA G.MATOVINA BRKO NIKOLA D.ZIVKOVIC maja J.popovic MARIJANA M.MILOVIC KOVACEVIC LAZAR S.popovic Department for Oncology Medical Faculty NisUniversity of NisNis18000Serbia Clinic of Oncology University Clinical Centre NisNis18000Serbia Department of Internal Medicine and Medical Sciences(DiMI) School of MedicineUniversity of GenovaGenova16100Italy Department of Medical Oncology U.O.C Clinica di Oncologia MedicaIRCCS Ospedale Policlinico San MartinoGenova16100Italy Department of General Medical Oncology and Multidisciplinary Breast Centre Leuven Cancer InstituteUniversity Hospitals LeuvenLeuven3001Belgium Department of Medical Oncology Oncology Institute of VojvodinaSremska Kamenica21208Serbia Department for Pathology Medical Faculty NisUniversity of NisNis18000Serbia Center for Pathology University Clinical Centre NisNis18000Serbia Faculty of Medicine University of Novi SadNovi Sad21000Serbia Department of Medical Oncology Institute of Oncology and Radiology SerbiaBelgrade11000Serbia

Oncofertility is an extremely signiﬁcant topic that is increasingly being discussed owing to increased evidence indicating that fertility preservation does not affect the treatment outcomes of patients with cancer but signiﬁcantly contributes to preserving life *** effect of chemotherapy can range from minimal effects to complete ovarian *** data are available on the effects of monoclonal antibodies and targeted therapies on the ovaries and *** ovarian suppression by administering a gonadotropin-releasing hormone agonist(GnRHa)during chemotherapy decreases the gonadotoxic effect of chemotherapy,thereby diminishing the chance of developing premature ovarian insufﬁciency(POI).At present,the concomitant administration of GnRH analogs during chemotherapy is the only accepted pharmacological method for preserving ovarian ***,most randomized studies on the effectiveness of luteinizing hormone-releasing hormone agonists during chemotherapy in preventing POI have been conducted in women with breast cancer,with a considerably small number of studies on patients with hematological ***,most randomized controlled trials on breast cancer have revealed a decrease in treatment-induced POI risk,regardless of the hormone receptor *** addition,studies on hematological malignancies have yielded negative results;nevertheless,theﬁndings must be interpreted with caution owing to numerous *** guidelines from the American Society of Clinical Oncology and ESMO Clinical Practice Guidelines recommend sperm,oocyte,and embryo cryopreservation as a standard practice and only offering GnRHa to patients when proven fertility preservation methods are not *** this manuscript,we present a comprehensive literature overview on the application of ovarian suppression with GnRHa during chemotherapy in patients with cancer by addressing preclinical and clinical data,as well as future perspectives in thisﬁeld

关键词： Gonadotropin-releasing hormone agonists(GnRHa) Fertility preservation Premature ovarian insufficiency(POI) Premenopausal patients

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Targeting triple-negative breast cancer:A clinical perspective

引用

Oncology Research 2023年第3期31卷 221-238页

作者： LAZAR S.popovic GORANA MATOVINA-BRKO maja popovic KEVIN PUNIE ANA CVETANOVIC MATTEO LAMBERTINI Department of Medical Oncology Oncology Institute of VojvodinaSremska KamenicaSerbia Faculty of Medicine University of Novi SadNovi SadSerbia Department of General Medical Oncology and Multidisciplinary Breast Centre Leuven Cancer InstituteUniversity Hospitals LeuvenLeuvenBelgium Department for Oncology Medical Faculty NisUniversity of NisNisSerbia Clinic of Oncology Clinical Centre NisNisSerbia Department of Internal Medicine and Medical Sciences(DiMI) School of MedicineUniversity of GenovaGenovaItaly Department of Medical Oncology U.O.C Clinica di Oncologia MedicaIRCCS Ospedale Policlinico San MartinoGenovaItaly

Triple-negative breast cancer(TNBC)is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast *** accounts for approximately 10%–15%of all diagnosed breast cancer cases and represents a high unmet need in the *** to just a few years ago,chemotherapy was the only systemic treatment option for this subtype(1).To date,TNBC is considered a heterogeneous *** of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases,in which Lehman et *** six subtypes of TNBC as follows:two basal-like(BL1 and BL2)subtypes,a mesenchymal(M)subtype,a mesenchymal stem-like(MSL)subtype,an immunomodulatory(IM)subtype,and a luminal androgen receptor(LAR)subtype(2).Later studies have demonstrated that the IM and MSL subtypes do not correlate with independent subtypes but reflect background expression by dense infiltration of tumor-infiltrating lymphocytes(TILs)or stromal *** to this finding,the classification of TNBC has been revised into the following four subtypes:basal 1,basal 2,LAR,and mesenchymal subtypes(3).Over the last years,several new strategies have been investigated for the treatment of patients with *** them,immunotherapy,antibody drug conjugates,new chemotherapy agents,and targeted therapy have been and are currently being *** present article aims to provide an updated overview on the different treatment options that are now available or are still under investigation for patients with TNBC.

关键词： Triple-negative breast cancer Immunotherapy Antibody-drug conjugates Target therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immunotherapy:A new standard in the treatment of metastatic clear cell renal cell carcinoma

引用

World Journal of Clinical Oncology 2022年第1期13卷 28-38页

作者： maja popovic Gorana Matovina-Brko Masa Jovic Lazar S popovic Department of Medical Oncology Oncology Institute of VojvodinaUniversity of Novi SadSremska Kamenica Faculty of Medicine University of Novi SadNovi Sad 21000Serbia

Renal cell cancer(RCC)represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney(90%).In the mid-nineties of the last century,the standard of treatment for patients with metastatic RCC was *** and pazopanib were registered in 2007 and 2009,respectively,and have since been the standard first-line treatment for metastatic clear cell RCC(mccRCC).Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells,including CD8+T lymphocytes,dendritic cells,natural killer cells(NK)and *** observation led to the design of new clinical trials in which patients were treated with *** the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system,the idea of combining angiogenic drugs with immunotherapy has emerged,and new clinical trials have been *** the last few years,several therapeutic options have been approved[immunotherapy and immunotherapy/tyrosine kinase inhibitors(TKI)]for the first-line treatment of ***/ipilimumab is approved for the treatment of patients with intermediate and poor *** checkpoint inhibitors(pembrolizumab,nivolumab,avelumab)in combination with TKI(axitinib,lenvatinib,cabozantinib)are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 *** is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.

关键词： Renal cell carcinoma Immunotherapy Checkpoint inhibitors Biomarkers Tumor microenvironment Programmed cell death 1 receptor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immunotherapy in the treatment of lymphoma

引用

World Journal of Stem Cells 2021年第6期13卷 503-520页

作者： Lazar S popovic Gorana Matovina-Brko maja popovic Milica popovic Ana Cvetanovic Ivan Nikolic Biljana Kukic Dragana Petrovic Department for Medical Oncology Oncology Institute of VojvodinaUniversity of Novi SadNovi Sad 21000Serbia Department for Medical Oncology Oncology Institute of VojvodinaNovi Sad 21000Serbia Department for Nephrology and Clinical Immunology Clinical Center of VojvodinaUniversity of Novi SadNovi Sad 21000Serbia Department for Medical Oncology Clinical Center of NisUniversity of NisNis 18000Serbia

Relapsed or refractory non-Hodgkin’s lymphomas,especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat *** who do not respond to initial therapy or experience relapse are treated with salvage regimens,and if eligible for aggressive therapy,treatment is continued with high-dose chemotherapy and autologous stem cell *** therapy options can cure substantial numbers of patients,however for some it is still an uncurable *** new drugs and cell therapies are being investigated for the treatment of relapsed or refractory *** types of immunotherapy options have shown promising results,and some have already become the standard of ***,we review immunotherapy options for the treatment of lymphoma and discuss the results,positions,practical aspects,and future directions of different drugs and cellular therapies for the treatment of this disease.

关键词： Immunotherapy Receptors Chimeric antigen Antibodies Monoclonal Immunoconjugates Hodgkin disease Lymphoma Large B-cell Diffuse

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：